EVX-01-arkiv - BioStock

Evaxion unveils genetic adjuvant technology to boost vaccines

Evaxion unveils genetic adjuvant technology to boost vaccines

7 June, 2023

Per Norlén, CEO Evaxion

Evaxion to sharpen focus and launch new platform

3 April, 2023

Patent

Evaxion receives phase IIb go-ahead from FDA

16 January, 2023

History behind Keytruda

Can Nordic companies extend the life of Keytruda?

1 December, 2022

Evaxion asset management

Evaxion Biotech Secures Equity Financing of up to 40 MUSD

10 June, 2022

Evaxion positive clinical momentum

Evaxion Biotech shows strong clinical momentum in Q1

16 May, 2022

Evaxion Biotech publishes EVX-01 data in scientific journal

Evaxion Biotech publishes EVX-01 data in scientific journal OncoImmunology

9 February, 2022

Green light for Evaxion Biotech for phase IIb study with EVX-01

Evaxion Biotech gets a go-ahead for phase IIb with EVX-01

24 January, 2022

Capital injection to financeEvaxion Biotechs phase IIb studies

Capital injection sets Evaxion Biotech up for phase IIb trials

25 November, 2021

Evaxion Biotech awarded by Frost & Sullivan

Evaxion Biotech awarded by Frost & Sullivan for its AI platform

18 October, 2021

12 Page 1 of 2